Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.

Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Pérez R, Arrieta O.

J Exp Clin Cancer Res. 2005 Dec;24(4):575-83.

PMID:
16471320
2.

Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.

Arrieta O, Guevara P, Reyes S, Ortiz A, Rembao D, Sotelo J.

Eur J Cancer. 1998 Dec;34(13):2101-6.

PMID:
10070318
3.

Investigation of immunosuppressive mechanisms in a mouse glioma model.

Ksendzovsky A, Feinstein D, Zengou R, Sharp A, Polak P, Lichtor T, Glick RP.

J Neurooncol. 2009 May;93(1):107-14. doi: 10.1007/s11060-009-9884-6. Epub 2009 May 9.

PMID:
19430886
4.

Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis.

Fabre RA, Pérez TM, Aguilar LD, Rangel MJ, Estrada-Garcìa I, Hernández-Pando R, Estrada Parra S.

Clin Exp Immunol. 2004 May;136(2):215-23.

5.

Topotecan enhances immune clearance of gliomas.

Wei J, DeAngulo G, Sun W, Hussain SF, Vasquez H, Jordan J, Weinberg J, Wolff J, Koshkina N, Heimberger AB.

Cancer Immunol Immunother. 2009 Feb;58(2):259-70. doi: 10.1007/s00262-008-0550-1. Epub 2008 Jul 2.

PMID:
18594817
6.

Localized BCNU chemotherapy and the multimodal management of malignant glioma.

La Rocca RV, Mehdorn HM.

Curr Med Res Opin. 2009 Jan;25(1):149-60. doi: 10.1185/03007990802611935 . Review.

PMID:
19210148
7.

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305.

8.
9.

CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis.

Sarkar S, Ghosh A, Mukherjee J, Chaudhuri S, Chaudhuri S.

Cancer Biol Ther. 2004 Nov;3(11):1121-8. Epub 2004 Nov 9.

PMID:
15467439
10.

Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.

Ren H, Tan X, Dong Y, Giese A, Chou TC, Rainov N, Yang B.

Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):241-52. doi: 10.1111/j.1742-7843.2008.00371.x. Epub 2009 Jan 21.

11.

Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells.

Wang P, Yu JP, Gao SY, An XM, Ren XB, Wang XG, Li WL.

Cell Immunol. 2008 May-Jun;253(1-2):59-65. doi: 10.1016/j.cellimm.2008.04.014. Epub 2008 Jun 5.

PMID:
18522858
12.

Immunotherapy for human glioma: innovative approaches and recent results.

Hussain SF, Heimberger AB.

Expert Rev Anticancer Ther. 2005 Oct;5(5):777-90. Review.

PMID:
16221048
13.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH.

Neuro Oncol. 2007 Jul;9(3):259-70. Epub 2007 May 23. Erratum in: Neuro Oncol. 2007 Oct;9(4):465.

14.

TLR ligands in the local treatment of established intracerebral murine gliomas.

Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ.

J Immunol. 2008 Nov 15;181(10):6720-9.

15.

Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.

Badn W, Hegardt P, Fellert MA, Darabi A, Esbjörnsson M, Smith KE, Janelidze S, Salford LG, Visse E, Siesjö P.

Scand J Immunol. 2007 Mar;65(3):289-97.

16.

The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.

Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, Lan L, Dewyngaert JK, Zagzag D, McBride WH, Formenti SC.

Clin Cancer Res. 2006 Aug 1;12(15):4730-7.

17.

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.

Mozaffari F, Lindemalm C, Choudhury A, Granstam-Björneklett H, Lekander M, Nilsson B, Ojutkangas ML, Osterborg A, Bergkvist L, Mellstedt H.

Cancer Immunol Immunother. 2009 Jan;58(1):111-20. doi: 10.1007/s00262-008-0530-5. Epub 2008 May 17.

PMID:
18488220
19.

Reduced glioma growth following dexamethasone or anti-angiopoietin 2 treatment.

Villeneuve J, Galarneau H, Beaudet MJ, Tremblay P, Chernomoretz A, Vallières L.

Brain Pathol. 2008 Jul;18(3):401-14. doi: 10.1111/j.1750-3639.2008.00139.x. Epub 2008 Mar 26.

PMID:
18371178
20.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645

Supplemental Content

Support Center